


CLAIMS

1. A compound of the following general formula (I):



(I)

5 wherein

R_2 designates hydrogen, Me, Et, CHO, CN, OH, OMe, COR₉, COOR₉, CONHR₉ or CSNHR₉, whereby R_9 denotes (C₁-C₄)alkyl;

R_5 designates hydrogen, (C₁-C₄)alkyl, OH, (C₁-C₄)alkoxy, OCF₃, trifluoromethyl or halogen;

10 R_6 designates Me, (C₁-C₄)alkoxy, OCF₃, SMe or SEt;

n is 1 or 2;

R_3' and R_5' each independently designate OH, Me, Et, OMe, OCF₃, trifluoromethyl or halogen;

15 U designates N or CR_{2'}, whereby R_2' denotes hydrogen, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, trifluoromethyl or halogen;

V designates N or CR_{4'}, whereby R_4' denotes hydrogen, (C₁-C₆)alkoxy, (C₁-C₆)alkyl, OH, trifluoromethyl or halogen;

W designates N or CR_{6'}, whereby R_6' denotes hydrogen, (C₁-C₄)alkyl, (C₁-C₄)alkoxy, trifluoromethyl or halogen;

20 and pharmaceutically acceptable salts thereof.

2. A compound according to claim 1, wherein R_2 desig-

nates Me, OH, CN, CHO, COR₉ or COOR₉.

3. A compound according to claim 1, wherein R₂ designates Me, CN, CHO or COMe.

5

4. A compound according to one of claims 1 to 3, wherein R₅ designates hydrogen, Me, OMe or halogen.

10

5. A compound according to one of claims 1 to 4, wherein R₆ designates OMe or OEt.

6. A compound according to one of claims 1 to 3, wherein R₅ designates hydrogen or OMe, preferably hydrogen; and R₆ designates OMe.

15

7. A compound according to one of claims 1 to 6, wherein R₃' and R₅' each independently designate chloro, bromo, Me or OMe.

20

8. A compound according to claim 1 to 7, wherein R₃' and R₅' are identical; or R₃' designates chloro or bromo, and R₅' designates OMe.

25

9. A compound according to claim 7, wherein R₃' and R₅' designate both chloro or both bromo.

10. A compound according to one of claims 1 to 9, wherein U and W designate CH and V designates CR₄'.

30

11. A compound according to claim 10, wherein R₄' designates hydrogen, chloro, bromo, Me or OMe.

12. A compound according to claim 10, wherein R₃' , R₄' and R₅' designate OMe; or R₃' designates chloro and R₄' and R₅' designate OMe; or R₄' designates hydrogen and R₃' and R₅' designate both chloro or both bromo.

5 13. A compound according to claim 1, which is 1-(3,5-dichlorophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-cyano-6-methoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-

10
15
20
25
30

cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-6-ethoxy-1,2,3,4-tetrahydroisoquinoline or 1-(3-chloro-4,5-dimethoxyphenyl)-2-cyano-6-ethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dichlorophenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dibromophenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,5-dimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3,4,5-trimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline 1-(3-chloro-4,5-dimethoxyphenyl)-2-formyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, 1-(3-chloro-4,5-dimethoxyphenyl)-2-acetyl-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline or 1-(3-chloro-4,5-

dimethoxyphenyl)-2-cyano-5,6-dimethoxy-1,2,3,4-tetrahydroisoquinoline, or a pharmaceutically acceptable salt thereof.

14. A compound according to anyone of claims 1 to 13, which is the (R)- or (S)-enantiomer.

5 15. A compound as defined in one of claims 1 to 14, for use as a medicament.

16. Use of a compound as defined in one of claims 1 to 14, for the preparation of a medicament for the prophylaxis or treatment of a disease in which down-regulation or inhibition of the expression or function of the IGF-1 receptor is
10 beneficial.

17. The use according to claim 16, wherein the disease is selected from cell proliferate diseases such as cancer, atherosclerosis, restenosis, inflammatory diseases such as
15 psoriasis, autoimmune diseases such as rheumatoid arthritis, and transplant rejection.

18. A method of treatment or prophylaxis of a disease in which down-regulation or inhibition of the expression or function of the IGF-1 receptor is beneficial, in a subject in
20 need of such treatment or prophylaxis, comprising administering to said subject an amount of a compound (I) as defined in one of claims 1 to 14 in an amount which is effective in down-regulating or inhibiting the expression or function of the IGF-1 receptor.

25 19. The method of claim 18, wherein the disease is selected from cell proliferate diseases such as cancer, athero-

sclerosis, restenosis, inflammatory diseases such as psoriasis, autoimmune diseases such as rheumatoid arthritis, and transplant rejection.

20. A pharmaceutical composition comprising a compound
5 of formula (I), or a pharmaceutically acceptable salt thereof
as defined in any one of claims 1 to 14, and a pharmaceuti-
cally acceptable adjuvant, diluent or carrier.

21. Articles containing a compound of the formula (I)
10 or a pharmaceutically acceptable salt thereof as defined in
any one of claims 1 to 14, and a chemotherapeutic agent, as a
combination for the simultaneous, separate or successive ad-
ministration in the therapy of a disease in which down-regu-
lation or inhibition of the expression or function of the
15 IGF-1 receptor is beneficial.

22. Use of a compound of the formula (I) or a pharma-
ceutically acceptable salt thereof as defined in any of
claims 1 to 14, as a pharmacological tool in the development
and standardization of in vitro and in vivo test systems for
20 the evaluation of the effects of inhibitors of cell cycle ac-
tivity in laboratory animals.